Afya Limited (AFYA) Balance Sheet

The balance sheet has consistently strengthened, with equity growing 29% since 2024Q1 while total liabilities increased only 16%, suggesting retained earnings are driving capital accumulation rather than leverage. This trajectory aligns with the prior cash flow analysis showing cumulative operating cash flow of $3.53B exceeding net income, reinforcing that earnings quality supports balance sheet expansion. The D/E ratio improved from 0.70 to 0.63 over the same period, indicating a gradual deleveraging trend despite ongoing M&A activity.

The D/E ratio of 0.63 remains below the peer average of approximately 0.30 for US-listed education companies, but Afya's higher leverage appears intentional to fund its consolidation strategy in Brazil's fragmented medical education market. The absolute debt level of $3.1B is substantial relative to equity, yet the stable trend over the last year suggests refinancing risk is contained, especially given the company's robust cash generation. Investors should monitor interest rate sensitivity, as a rising rate environment could increase the cost of this debt, though the current ratio of 2.20 provides a liquidity buffer.

The stability of goodwill at $1.5B over the last five quarters suggests no major impairments, but the concentration of intangibles from past acquisitions warrants scrutiny, as any regulatory shift reducing medical seat scarcity could impair these values. PPE growth from $1.4B to $1.6B indicates continued investment in physical campuses, consistent with the high fixed-cost base described in the business model. The asset mix, with 17% in PPE and 16% in goodwill, reflects a hybrid model that is neither purely asset-light nor asset-heavy, but the intangibles risk is elevated given the regulatory dependence of medical licenses.

The equity base of $4.9B is almost entirely composed of retained earnings, which grew consistently each quarter, reflecting the company's ability to convert its high-margin medical education revenue into book value. The absence of significant dilution is notable, as equity growth outpaced the modest increase in total assets, suggesting management is not issuing shares to fund acquisitions. This high-quality equity structure supports the balance sheet signal of 'Adequate', as it provides a cushion against potential impairments or regulatory shocks.

The sharp recovery in the current ratio from below 1.0 in mid-2025 to 2.20 in 2026Q2 suggests improved working capital management, likely driven by better tuition collection cycles and reduced short-term liabilities. Cash of $1.0B covers approximately 32% of total debt, providing a meaningful buffer against refinancing needs, though the cash position dipped from $1.3B in 2026Q1, indicating deployment toward acquisitions or buybacks. This liquidity strength is consistent with the prior cash flow analysis showing strong operating cash conversion, but investors should note the seasonal volatility in the current ratio, which fell to 0.94 in 2025Q2.

The decline in deferred revenue from $158M in 2025Q4 to $104M in 2026Q2 may indicate a seasonal pattern of tuition recognition, but it also warrants monitoring for any structural slowdown in new enrollments. Given the multi-year nature of medical degrees, deferred revenue represents only a small fraction of total future revenue, as most tuition is recognized over the academic year rather than upfront. The stability of this metric, despite regulatory overhangs, suggests demand for medical seats remains robust, but the lack of explicit forward guidance in the latest quarter limits visibility into future enrollment trends.